- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07942350
AI-Powered Chatbot Integrated With Wearable-Derived Data for Promoting Mental Health Among Finnish Higher Education Students
Mental health problems among adolescents and young adults have increased globally, underscoring the urgent need for accessible, preventive, and systemic approaches to promoting student mental health. This pilot study aims to evaluate the feasibility, conversational quality, and preliminary effectiveness of an AI-powered chatbot integrated with wearable-derived physiological data intervention to provide personalized and timely mental health support for Finnish higher education students. The study explores how real-time stress indicators, such as heart rate variability (HRV), can inform the chatbot's adaptive and proactive interactions to promote students' mental health in daily life.
The study setting will be the Faculty of Medicine, University of Turku in Finland. A total of 15-20 participants will be recruited with convenience sampling for this study. The inclusion criteria for participants are: 1) enrolled students at the Faculty of Medicine, 2) voluntary and consenting, 3) Finnish-speaking, 4) having a smart phone (Android/iOS), and 5) having none to mild levels of psychological distress. Participants who self-report a diagnosis of mental health disorder, or having an acute treatment for mental health will be excluded.
The intervention in this study consists of 4-week daily use of a AI-powered chatbot. In addition to access to the chatbot, a wearable device will be given to each participant to collect physiological data related to their stress (HRV), physical activity and sleep. At the end of week 2 and 3 of the study, participants will receive a personalized report summarizing the data collected by the device. Throughout the intervention period, the research assistant will contact participants once a week to ensure their well-being. At the end of the study, an interview will be arranged with each participant.
The study data includes the conversations with the chatbot, physiological data from the wearable device, daily stress questions, background information questionnaire, Depression Anxiety Stress Scale (DASS-21) (at the beginning of the intervention and at weeks 2 and 4), Chatbot Usability Questionnaire (CUQ) (at weeks 2 and 4) and an end-of-study semi-structured interview.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Anna Axelin
- Numéro de téléphone: +358405029905
- E-mail: anmaax@utu.fi
Lieux d'étude
-
-
-
Turku, Finlande
- Recrutement
- University of Turku
-
Contact:
- Anna Axelin
- Numéro de téléphone: +358405029905
- E-mail: anmaax@utu.fi
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Study population consists of higher education students.
La description
Inclusion Criteria:
- enrolled students at the Faculty of Medicine (bachelor's, master's, or doctoral level students)
- voluntary and consenting
- Finnish-speaking (native speaker or enrolled in a Finnish study program)
- having a smart phone (Android/iOS)
- having none to mild levels of psychological distress
Exclusion Criteria:
- self-reported diagnosis of mental health disorder, or having an acute treatment for mental health
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: OTHER
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Higher education students
|
Daily use of an AI-powered chatbot and a wearable device to collect physiological data related to stress, physical activity and sleep. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Eligibility of participants
Délai: 4 weeks
|
The number of individuals screened, the proportion that meets the inclusion criteria, and the main reasons for exclusion will be documented to assess the appropriateness and practicality of the eligibility criteria. |
4 weeks
|
|
Recruitment and retention of participants
Délai: 4 weeks
|
The number of participants enrolled, the proportion completing the whole intervention as well as assessments, and attrition rates will be recorded to evaluate recruitment efficiency and participant retention. |
4 weeks
|
|
Engagement of the participants
Délai: 4 weeks
|
Quantitative indicators that include the frequency of chatbot interactions, average session length, and response rates will be analyzed to assess adherence to study procedures and sustained engagement over time. |
4 weeks
|
|
Technical performance of the chatbot
Délai: 4 weeks
|
System reliability will be examined through logs of technical errors, data integration issues, and chatbot downtime events, providing insights into the stability and operational consistency of the intervention platform. |
4 weeks
|
|
Safety of the chatbot
Délai: 4 weeks
|
It will be assessed whether the chatbot's interactions are free from harm and whether it can appropriately identify and manage high-risk user input. Evaluation focuses on the chatbot's ability to detect and respond to indications of severe distress or crisis, such as expressions of self-harm, suicidal ideation, abuse, or other high-risk situations. Following the MHealth-EVAL framework (Chen et al., 2024), responses will be annotated using a binary scale, where "0" indicates the presence of harmful or unsafe content or failure to address crisis cues appropriately, and "1" indicates a safe and supportive response. |
4 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Psychological distress
Délai: 4 weeks
|
Psychological distress will be assessed using the Depression Anxiety Stress Scales-21 (DASS-21), which is a 21-item self-report instrument measuring three dimensions of negative emotional states: depression, anxiety, and general stress. Each subscale includes seven items rated on a 4-point Likert scale (0-3), with higher scores indicating greater symptom severity. DASS-21 will be administered before, at two weeks, and after the intervention to assess potential changes in participants' psychological stress. |
4 weeks
|
|
Behavioral change and health literacy
Délai: 4 weeks
|
At the end of the 4-week intervention, semi-structured interviews will be conducted with each participant individually to gain an in-depth understanding of their experiences with the chatbot as well as any behavioral changes they perceived during the study. In addition, the participants' understanding of AI health literacy will be discussed. |
4 weeks
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- TY/2154/2025
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Dataset may be made available for secondary use through the international open science repository Dryad. Identifiers will be removed from the dataset to ensure that individual participants cannot be identified. Secondary use of the data requires a permission process that adheres to established research ethics principles.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .